SCHEMBL3345151

SCHEMBL3345151

CC(C)(N)C(=O)OC1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.47
EPHX1 P07099 2/20 0.41
NAAA Q02083 2/20 0.39
CHRM3 P20309 5/20 0.38
HTT P42858 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
CA12 O43570 2/20 0.35
CA9 Q16790 2/20 0.35
CYP2C19 P33261 1/20 0.35
ATM Q13315 1/20 0.34
DPP4 P27487 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673661 0.98 CYP19A1 (0.50) CYP19A1EPHX1NAAACHRM3HTT
Hydrochloric Acid SCHEMBL185528 0.98 CYP19A1 (0.46) CYP19A1EPHX1NAAACHRM3HTT
Hydrochloric Acid SCHEMBL18954563 0.96 CYP19A1 (0.49) CYP19A1EPHX1NAAACHRM3HTT
SCHEMBL21103611 0.96 CYP19A1 (0.44) CYP19A1EPHX1NAAACHRM3HTT
Hydrochloric Acid SCHEMBL18954396 0.94 CYP19A1 (0.42) CYP19A1EPHX1NAAACHRM3HTT
SCHEMBL16575246 0.83 CYP19A1 (0.45) CYP19A1EPHX1NAAACHRM3HTT
SCHEMBL21796112 0.83 CYP19A1 (0.35) CYP19A1NAAACHRM3HTTSMN1; SMN2
SCHEMBL1682649 0.82 CYP19A1 (0.50) CYP19A1EPHX1NAAACHRM3HTT
SCHEMBL21305857 0.82 KAT2B (0.36) CYP19A1CHRM3SMN1; SMN2ATMDPP4
SCHEMBL24326577 0.81 CYP19A1 (0.35) CYP19A1CHRM3CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112708052-B Ether viscosity-reducing hydration regulator and preparation method thereof 科之杰新材料集团(贵州)有限公司 2022-10-25 CN disclosed
CN-112708056-B Viscosity-reducing polycarboxylate superplasticizer for concrete member and preparation method thereof 科之杰新材料集团河南有限公司 2022-10-18 CN disclosed
CN-112708056-A Viscosity-reducing polycarboxylate superplasticizer for concrete member and preparation method thereof 科之杰新材料集团河南有限公司 2021-04-27 CN disclosed
CN-112708052-A Ether viscosity-reducing hydration regulator and preparation method thereof 科之杰新材料集团(贵州)有限公司 2021-04-27 CN disclosed
US-10745428-B2 Antiviral phosphodiamide prodrugs of tenofovir IDENIX PHARMACEUTICALS LLC (US) 2020-08-18 US disclosed
US-10736908-B2 Antiviral aryl-amide phosphodiamide compounds MERCK SHARP & DOHME CORP. (US) 2020-08-11 US disclosed
US-10449208-B2 Antiviral prodrugs of tenofovir MERCK SHARP & DOHME CORP. (US) 2019-10-22 US disclosed
US-20190262365-A1 ANTIVIRAL ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2019-08-29 US disclosed
US-20190183912-A1 ANTIVIRAL PRODRUGS OF TENOFOVIR MERCK SHARP & DOHME CORP. (US) 2019-06-20 US disclosed
EP-2864318-B1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS MACROPHAGE PHARMA LTD (GB) 2017-08-09 EP disclosed
WO-2010097586-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2010-09-02 WO disclosed
WO-2010043865-A1 INHIBITORS OF HSP90 CHROMA THERAPEUTICS LTD (GB) 2010-04-22 WO disclosed
WO-2010043865-A1 INHIBITORS OF HSP90 CHROMA THERAPEUTICS LTD (GB) 2010-04-22 WO disclosed
WO-2009141575-A1 INHIBITORS OF PLK CHROMA THERAPEUTICS LTD. (GB) 2009-11-26 WO disclosed
WO-2009130475-A1 SUBSTITUTED THIOPHENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS CHROMA THERAPEUTICS LTD., (GB) 2009-10-29 WO disclosed
WO-2009106848-A2 ENZYME AND RECEPTOR MODULATION CHROMA THERAPEUTICS LTD. (GB) 2009-09-03 WO disclosed
WO-2009106844-A1 INHIBITORS OF P38 MAP KINASE CHROMA THERAPEUTICS LTD. (GB) 2009-09-03 WO disclosed
EP-1095935-B1 6-Hydroxy-5,6-dihydrouracils as herbicides SUMITOMO CHEMICAL CO (JP) 2008-12-17 EP disclosed
US-6410484-B1 ACTIVE MATERIAL; CONTROLLING WEEDS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-06-25 US disclosed
EP-1095935-A1 6-Hydroxy-5,6-dihydrouracils as herbicides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10736908-B2 Antiviral aryl-amide phosphodiamide compounds PNP, TYMP, DUT CYP19A1 1127/4885EPHX1 2888/4885NAAA 59/4885
US-20190183912-A1 ANTIVIRAL PRODRUGS OF TENOFOVIR PNP, TYMP, HPRT1 CYP19A1 1189/4885EPHX1 3009/4885NAAA 657/4885
US-10449208-B2 Antiviral prodrugs of tenofovir PNP, TYMP, HPRT1 CYP19A1 1189/4885EPHX1 3009/4885NAAA 657/4885
US-10745428-B2 Antiviral phosphodiamide prodrugs of tenofovir PNP, TYMP, PPA1 CYP19A1 1677/4885EPHX1 2862/4885NAAA 285/4885
US-20190262365-A1 ANTIVIRAL ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS PNP, TYMP, DUT CYP19A1 1127/4885EPHX1 2888/4885NAAA 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.